AMIX

Autonomix Medical, Inc. (AMIX) Economic Moat Analysis (2026)

Invetso Score: 1.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 1.0 (Weak)

AMIX has no provided evidence of proprietary brands, patents, or regulatory licenses that would let it sustain pricing power versus peers.

The negative TTM ROIC suggests any intangible advantage is not translating into durable excess returns relative to competitors.

With no disclosed margin history or long-run profitability data, there is no filing-based support for a differentiated intangible moat.

Switching Costs

Score:

The available metrics do not show retention-linked economics, so customer lock-in cannot be inferred as a durable advantage versus peers.

Negative ROIC and zero asset turnover indicate the business is not currently monetizing any switching friction into stable returns.

Without evidence of embedded workflows, contractual lock-in, or compliance dependence, switching costs appear low relative to stronger peer franchises.

Network Effects

Score:

No provided filings or third-party evidence indicate a user, data, or ecosystem flywheel that compounds value versus peers.

The negative profitability profile is inconsistent with a network-driven moat that would normally support expanding margins and retention.

Absent proof of scale-driven participant dependence, network effects cannot be credited as a meaningful structural advantage.

Cost Advantage

Score:

TTM ROIC below zero indicates AMIX is not demonstrating a cost position that converts into superior capital efficiency versus peers.

The lack of gross and operating margin history prevents evidence of persistent unit-cost advantage over competitors.

Zero asset turnover and negative returns together argue against a durable cost edge that would protect margins over a 5–10 year horizon.

Efficient Scale

Score:

No evidence shows AMIX operates in a niche where a small number of firms can profitably serve the market better than peers.

Negative ROIC suggests the company is not capturing the economics typically associated with efficient-scale protection.

Without filing evidence of regulated scarcity or natural monopoly characteristics, efficient scale appears absent.

Overall Score

Score:

AMIX shows no evidenced structural moat in the supplied data, and its negative TTM ROIC plus missing margin history point to weak pricing power, weak retention, and no durable peer-relative advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Autonomix Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →